Currently, an anti-sortilin monoclonal antibody (GSK4527226), increasing progranulin levels in plasma and brain via inhibiting its binding with Sortilin, is entering a Phase 2 clinical trial to assess safety and efficacy in patients with early AD [88]. Here, GRN is linked to Alzheimer disease.